Repare Therapeutics Inc. (NasdaqGM: RPTX)
Health Care · Biotechnology · CA
$—
— today · — 1Y
Repare Therapeutics Inc. (NasdaqGM: RPTX) operates in the Biotechnology industry within the Health Care sector.
trading between 1.56 and 2.66.
Tweenvest scores Repare Therapeutics Inc. across four factors: quality 27/100, value 54/100. Its strongest factor is value.
RPTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $11.87M
- P/E
- —
- EPS
- -1.69
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $2.66
- 52-week low
- $1.56
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 129
- Next earnings
- —
About Repare Therapeutics Inc.
Repare Therapeutics Inc. is a precision oncology biopharmaceutical company in the clinical stage, focused on discovering and developing innovative therapies. Operating across Canada and the United States, the company leverages a synthetic lethality approach to identify new treatments. Central to their efforts is the proprietary, genome-wide, and CRISPR-enabled SNIPRx platform, which systematically uncovers and advances highly targeted cancer medicines. These therapies are specifically designed to address genomic instability, particularly related to DNA damage repair mechanisms. Their primary investigational drug is RP-3500, an oral small molecule inhibitor currently being developed to treat solid tumors that possess specific genomic alterations linked to DNA damage repair. Repare is also advancing RP-6306, which is in Phase I clinical trials for tumors characterized by genetic alterations involving CCNE1 amplification. Furthermore, the company is pursuing a Polymerase Theta program, investigating a synthetic lethal target relevant to BRCA mutations and other genomic abnormalities. Repare Therapeutics Inc. was established in 2016 and maintains its headquarters in Montreal, Canada.
- Founded
- 2016
- Listed since
- Jun 19, 2020
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.